Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Gilles Salles1, Stephen J. Schuster2, Sven de Vos3, Nina D. Wagner‐Johnston4, Andreas Viardot5, Kristie A. Blum6, Christopher R. Flowers7, Wojciech Jurczak8, Ian W. Flinn9, Brad S. Kahl10, Peter Martin11, Yeonhee Kim12, Sanatan Shreay12, Matthias Will13, Bess Sorensen13, Madlaina Breuleux13, Pier Luigi Zinzani14, Ajay K. Gopal15
1Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France
2Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
3Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
4Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA
5Department of Internal Medicine III, University Hospital of Ulm, Germany
6Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA
7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
8Department of Hematology, Jagiellonian University, Krakow, Poland
9Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA
10Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO, USA
11Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA
12Gilead Sciences, Inc., Foster City, CA, USA
13At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA
14Institute of Hematology and Oncology, University of Bologna, Italy
15Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Haematologica
Tập 102 Số 4
e156-e159
Thông tin tác giả